Necrostatin-1

Specifications / Handling

More Information
Product Details
Synonyms	Nec-1; MTH-Trp; MTH-DL-Tryptophan; Methyl-thiohydantoin DL-tryptophan; 5-(1H-Indol-3-ylmethyl)-3-methyl-2-thioxo-4-imidazolidinone
Product Type	Chemical
Properties
Formula	C₁₃H₁₃N₃OS
MW	259.3
CAS	4311-88-0
Purity Chemicals	≥98% (HPLC)
Appearance	Off-white to yellow solid.
Solubility	Soluble in DMSO, ethanol or dimethylformamide.
Other Product Data	Note:1 Necrostatin-1 is sparingly soluble in aqueous buffers. For a maximum solubility in aqueous buffers, it should first be dissolved in DMF and then diluted with the aqueous buffer of choice. The solubility is approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We recommend to store aqueous solutions not longer than one day. Note:2 In solution the product slightly tautomerizes. In polar solvents there is more enol form while in non-polar solvents there is more keto form.
InChi Key	TXUWMXQFNYDOEZ-UHFFFAOYSA-N
Smiles	CN1C(=S)NC(CC2=CNC3=CC=CC=C23)C1=O
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	Keep under inert gas. Protect from light.
Use/Stability	Stable for at least 2 years after receipt when stored at -20°C. Stock solutions are stable for at least 3 months when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

Competitive indoleamine 2,3-dioxygenase (IDO) inhibitor [1, 4, 9, 10].
Cell permeable, potent and selective necroptosis (a non-apoptotic form of programmed cell death) inhibitor [2, 5].
Showed neuroprotection in a murine model of ischemic brain injury in vivo [2, 3].
Selective and ATP-competitive receptor-interacting protein kinase 1 (RIPK1) inhibitor [6, 7].
Used in inflammatory and degenerative disease models to target RIPK1 [7, 9, 10].
Suppresses autophagy and apoptosis in murine brain injury models [8, 9].
Cardioprotective and neuroprotective [11-14].

Product References

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy: A.J. Muller, et al.; Nat. Med. 11, 312 (2005)
Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury: A. Degterev, et al.; Nat. Chem. Biol. 1, 112 (2005)
Necrostatin-1 protects against glutamate-induced glutathione depletion and caspase-independent cell death in HT-22 cells: X. Xu, et al.; J. Neurochem. 103, 2004 (2007)
Clinical aspects of indoleamine 2,3-dioxygenase (IDO)-initiated tryptophan metabolism: IDO is a target of drug discovery for various diseasea: O. Takikawa; Int. Congr. Ser. 1304, 290 (2007)
Chemical genetic approaches to probing cell death: B.R. Stockwell & N.M. Gangadhar; Curr. Opin. Chem. Biol. 11, 83 (2007)
Identification of RIP1 kinase as a specific cellular target of necrostatins: A. Degterev, et al.; Nat. Chem. Biol. 4, 313 (2008)
RIP1-dependent and independent effects of necrostatin-1 in necrosis and T cell activation: Y. Cho, et al.; PLoS One 6, e23209 (2011)
Necrostatin-1 suppresses autophagy and apoptosis in mice traumatic brain injury model: Y.Q. Wang, et al.; Neurochem. Res. 37, 1849 (2012)
Necrostatin-1 blocks both RIPK1 and IDO: consequences for the study of cell death in experimental disease models: P. Vandenabeele, et al.; Cell Death Differ. 20, 185 (2013)
Activity and specificity of necrostatin-1, small-molecule inhibitor of RIP1 kinase: A. Degterev, et al.; Cell Death Differ 20, 366 (2013)
Study of cardioprotective effects of necroptosis inhibitors on isolated rat heart subjected to global ischemia-reperfusion: Y.V. Dimitriev, et al.; Bull. Exp. Biol. Med. 155, 245 (2013)
Necroptosis inhibitor necrostatin-1 promotes cell protection and physiological function in traumatic spinal cord injury: Y. Wang, et al.; Neuroscience 266, 91 (2014)
Necrostatin-1 protection of dopaminergic neurons; J.R. Wu, et al.; Neural. Regen. Res. 10, 1120 (2015)
Protective role of necrostatin-1 in acute myocardial infarction: F. Carbone, et al.; Eur. J. Clin. Invest. 46, 99 (2016)
Stratification of lung squamous cell carcinoma based on ferroptosis regulators: Potential for new therapeutic strategies involving ferroptosis induction: A. Asakawa, et al.; Lung Cancer 165, 82 (2022)

Call	+41 61 926 6040
Fax	+41 61 926 6049